Latest & greatest articles for constipation

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on constipation or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on constipation and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for constipation

121. A 12-Week, Randomized, Controlled Trial With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Linaclotide in Irritable Bowel Syndrome With Constipation Full Text available with Trip Pro

A 12-Week, Randomized, Controlled Trial With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Linaclotide in Irritable Bowel Syndrome With Constipation Linaclotide is a minimally absorbed guanylate cyclase-C agonist. The objective of this trial was to determine the efficacy and safety of linaclotide in patients with irritable bowel syndrome with constipation (IBS-C).This phase 3, double-blind, parallel-group, placebo-controlled trial randomized IBS-C patients

2012 EvidenceUpdates Controlled trial quality: predicted high

122. Linaclotide for Irritable Bowel Syndrome With Constipation: A 26-Week, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Efficacy and Safety (Abstract)

Linaclotide for Irritable Bowel Syndrome With Constipation: A 26-Week, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Efficacy and Safety Linaclotide is a minimally absorbed peptide guanylate cyclase-C agonist. The objective of this trial was to determine the efficacy and safety of linaclotide treatment in patients with irritable bowel syndrome with constipation (IBS-C) over 26 weeks.This phase 3, double-blind, parallel-group, placebo-controlled trial randomized IBS-C patients

2012 EvidenceUpdates Controlled trial quality: predicted high

123. Lubiprostone (Amitiza) for chronic idiopathic constipation

Lubiprostone (Amitiza) for chronic idiopathic constipation Lubiprostone (Amitiza) for chronic idiopathic constipation Lubiprostone (Amitiza) for chronic idiopathic constipation NIHR HSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSC. Lubiprostone (Amitiza) for chronic idiopathic constipation. Birmingham: NIHR Horizon Scanning (...) Centre (NIHR HSC). Horizon Scanning Review. 2012 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Alprostadil; Chronic Disease; Constipations Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston

2012 Health Technology Assessment (HTA) Database.

124. Lubiprostone (Amitiza) for opioid-induced constipation in patients with chronic non-cancer pain

Lubiprostone (Amitiza) for opioid-induced constipation in patients with chronic non-cancer pain Lubiprostone (Amitiza) for opioid-induced constipation in patients with chronic non-cancer pain Lubiprostone (Amitiza) for opioid-induced constipation in patients with chronic non-cancer pain NIHR HSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database (...) . Citation NIHR HSC. Lubiprostone (Amitiza) for opioid-induced constipation in patients with chronic non-cancer pain. Birmingham: NIHR Horizon Scanning Centre (NIHR HSC). Horizon Scanning Review. 2012 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Alprostadils; Chronic Pain; Constipation Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence The NIHR Horizon Scanning Centre, Department

2012 Health Technology Assessment (HTA) Database.

125. Naloxegol (NKTR-118) for opioid-induced constipation

Naloxegol (NKTR-118) for opioid-induced constipation Naloxegol (NKTR-118) for opioid-induced constipation Naloxegol (NKTR-118) for opioid-induced constipation NHSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NHSC. Naloxegol (NKTR-118) for opioid-induced constipation. Birmingham: National Horizon Scanning Centre (NHSC). Horizon (...) Scanning Review. 2012 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Analgesics, Opioids; Constipation; Laxatives; Naltrexone Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15

2012 Health Technology Assessment (HTA) Database.

126. Oxycodone HCI / naloxone HCI - Pain, Moderate to severe and relief of opioid-induced constipation

Oxycodone HCI / naloxone HCI - Pain, Moderate to severe and relief of opioid-induced constipation Common Drug Review CDEC Meeting – November 16, 2011; CDEC Reconsideration – January 18, 2012 Notice of CDEC Final Recommendation – January 25, 2012 Page 1 of 6 © 2012 CADTH CDEC FINAL RECOMMENDATION OXYCODONE HYDROCHLORIDE/NALOXONE HYDROCHLORIDE RESUBMISSION (Targin – Purdue Pharma) Indication: Relief of Moderate to Severe Pain and Opioid-Induced Constipation Recommendation: The Canadian Drug (...) Expert Committee (CDEC) recommends that oxycodone hydrochloride/naloxone hydrochloride controlled release (CR) (Targin) not be listed. Reason for the Recommendation: The comparative clinical benefit of oxycodone/naloxone CR in patients with moderate to severe chronic pain and opioid-induced constipation is not established, because there are no randomized controlled trials (RCTs) comparing oxycodone/naloxone CR with less expensive opioid treatment in combination with an optimized laxative regimen

2012 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

127. Wireless motility capsule in the diagnosis and evaluation of gastroparesis or slow-transit constipation

Wireless motility capsule in the diagnosis and evaluation of gastroparesis or slow-transit constipation Wireless motility capsule in the diagnosis and evaluation of gastroparesis or slow-transit constipation Wireless motility capsule in the diagnosis and evaluation of gastroparesis or slow-transit constipation BlueCross BlueShield Association Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made (...) for the HTA database. Citation BlueCross BlueShield Association. Wireless motility capsule in the diagnosis and evaluation of gastroparesis or slow-transit constipation. Chicago: BlueCross BlueShield Association (BCBS). TEC Assessment 27(4). 2012 Authors' objectives The objective of this assessment is to determine whether the wireless motility capsule (SmartPill®) improves health outcomes when used in the diagnosis and evaluation of gastroparesis and constipation, in patients presenting with clinical

2012 Health Technology Assessment (HTA) Database.

128. Overactive bladder drugs and constipation: a meta-analysis of randomized, placebo-controlled trials

Overactive bladder drugs and constipation: a meta-analysis of randomized, placebo-controlled trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2011 DARE.

129. Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation (Abstract)

Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation Linaclotide, a minimally absorbed, 14-amino acid peptide agonist of guanylate cyclase-C, has shown benefit in a proof-of-concept study for the treatment of patients with irritable bowel syndrome (IBS) with constipation (IBS-C). We assessed the efficacy and safety of linaclotide at a daily dose range of 75-600 μg in IBS-C.We performed a randomized, double-blind

2011 EvidenceUpdates Controlled trial quality: predicted high

130. Randomised controlled trial: Two weeks of rifaximin relieves global symptoms and bloating in people with IBS without constipation

Randomised controlled trial: Two weeks of rifaximin relieves global symptoms and bloating in people with IBS without constipation Two weeks of rifaximin relieves global symptoms and bloating in people with IBS without constipation | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Two weeks of rifaximin relieves global symptoms and bloating in people with IBS without constipation Article Text Therapeutics Randomised controlled trial Two weeks

2011 Evidence-Based Medicine

131. Managing functional constipation in children

Managing functional constipation in children Constipation is a common childhood problem, with both somatic and psychological effects. The etiology of paediatric constipation is likely multifactorial, and seldom due to organic pathology. Children benefit from prompt and thorough management of this disorder. The goal of treatment is to produce soft, painless stools and to prevent reaccumulation of feces. Education, behavioural modification, daily maintenance stool softeners and dietary (...) modification are all important components of therapy. Fecal disimpaction may be necessary at the outset of treatment. Investigations are rarely necessary. Polyethylene glycol is a safe, effective and well-tolerated long-term treatment for constipation. Regular follow-up for children with constipation is important. Referral to a gastroenterologist should be made in refractory cases or when there is a suspicion of organic pathology. Key Words: Constipation; Encopresis; Laxative; Paediatric

2011 Canadian Paediatric Society

132. Systematic review: Polyethylene glycol more effective than lactulose for relief of chronic constipation

Systematic review: Polyethylene glycol more effective than lactulose for relief of chronic constipation Polyethylene glycol more effective than lactulose for relief of chronic constipation | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Polyethylene glycol more effective than lactulose for relief of chronic constipation Article Text Primary health care Systematic review Polyethylene glycol more effective than lactulose for relief of chronic

2011 Evidence-Based Nursing

133. Rifaximin therapy for patients with irritable bowel syndrome without constipation. Full Text available with Trip Pro

Rifaximin therapy for patients with irritable bowel syndrome without constipation. Evidence suggests that gut flora may play an important role in the pathophysiology of the irritable bowel syndrome (IBS). We evaluated rifaximin, a minimally absorbed antibiotic, as treatment for IBS.In two identically designed, phase 3, double-blind, placebo-controlled trials (TARGET 1 and TARGET 2), patients who had IBS without constipation were randomly assigned to either rifaximin at a dose of 550 mg (...) groups.Among patients who had IBS without constipation, treatment with rifaximin for 2 weeks provided significant relief of IBS symptoms, bloating, abdominal pain, and loose or watery stools. (Funded by Salix Pharmaceuticals; ClinicalTrials.gov numbers, NCT00731679 and NCT00724126.).

2011 NEJM Controlled trial quality: predicted high

134. Two randomized trials of linaclotide for chronic constipation. Full Text available with Trip Pro

Two randomized trials of linaclotide for chronic constipation. Linaclotide is a minimally absorbed peptide agonist of the guanylate cyclase C receptor. In two trials, we aimed to determine the efficacy and safety of linaclotide in patients with chronic constipation.We conducted two randomized, 12-week, multicenter, double-blind, parallel-group, placebo-controlled, dual-dose trials (Trials 303 and 01) involving 1276 patients with chronic constipation. Patients received either placebo (...) symptoms in patients with chronic constipation. Additional studies are needed to evaluate the potential long-term risks and benefits of linaclotide in chronic constipation. (Funded by Ironwood Pharmaceuticals and Forest Research Institute; ClinicalTrials.gov numbers, NCT00765882 and NCT00730015.).

2011 NEJM Controlled trial quality: predicted high

135. Lactobacillus reuteri (DSM 17938) in infants with functional chronic constipation: a double-blind, randomized, placebo-controlled study (Abstract)

Lactobacillus reuteri (DSM 17938) in infants with functional chronic constipation: a double-blind, randomized, placebo-controlled study To evaluate the beneficial effects of Lactobacillus reuteri (DSM 17938) in infants with functional chronic constipation.A double-blind, placebo-controlled, randomized study was conducted from January 2008 to December 2008 in 44 consecutive infants at least 6 months old (mean age+/-SD, 8.2+/-2.4 SD; male/female, 24/20) admitted to the Gastrointestinal Endoscopy (...) and Motility Unit of the Department of Pediatrics, University "Federico II" of Naples, with a diagnosis of functional chronic constipation. The 44 infants with chronic constipation were randomly assigned to 2 groups: group A (n=22) received supplementation with the probiotic L reuteri (DSM 17938) and group B (n=22) received an identical placebo. Primary outcome measures were frequency of bowel movements per week, stool consistency, and presence of inconsolable crying episodes, recorded in a daily diary

2010 EvidenceUpdates Controlled trial quality: predicted high

136. Chenodeoxycholate in females with irritable bowel syndrome-constipation: a pharmacodynamic and pharmacogenetic analysis Full Text available with Trip Pro

Chenodeoxycholate in females with irritable bowel syndrome-constipation: a pharmacodynamic and pharmacogenetic analysis Sodium chenodeoxycholate (CDC) accelerates colonic transit in health. Our aim was to examine pharmacodynamics (colonic transit, bowel function) and pharmacogenetics of CDC in constipation-predominant irritable bowel syndrome (IBS-C).In a double-blind placebo-controlled study, 36 female patients with IBS-C were randomized to treatment with delayed-release oral formulations

2010 EvidenceUpdates Controlled trial quality: uncertain

137. Abdominal massage for people with constipation: a cost utility analysis Full Text available with Trip Pro

Abdominal massage for people with constipation: a cost utility analysis This paper is a report of a study conducted to evaluate change in health-related quality of life for people with constipation receiving abdominal massage and to estimate the cost-effectiveness of two alternative scenarios developed from the original trial.Constipation is a common problem and is associated with decrease in quality of life. Abdominal massage appears to decrease the severity of gastrointestinal symptoms (...) and eventually approached euro8300. For 'professional massage', the cost per quality adjusted life year was euro60,000 and eventually dropped to euro28,000.Abdominal massage may be cost-effective in the long-term and it is relevant to consider it when managing constipation. A crucial aspect will be to identify those who will benefit.

2010 EvidenceUpdates Controlled trial quality: uncertain

138. Digital rectal exams in children who present with constipation

Digital rectal exams in children who present with constipation BestBets: Digital rectal exams in children who present with constipation Digital rectal exams in children who present with constipation Report By: Nesba Naheed - Medical Student Search checked by Rachel Jenner - Consultant in Emergency Medicine Institution: Manchester Royal Infirmary Date Submitted: 5th June 2007 Date Completed: 8th June 2010 Last Modified: 8th June 2010 Status: Green (complete) Three Part Question In a [child (...) presenting with constipation] is a [digital rectal examination] recommended to [confirm the diagnosis]? Clinical Scenario A five year boy is presented to the Emergency department by his mother. His mother complains that he has constipation. After examining the boy's abdomen you wonder whether in order to confirm the diagnosis you should perform a digital rectal exam (DRE). Search Strategy Medline using the OVID interface 1950 to January Week 2 2010: (constipation.mp OR exp Constipation/ exp Feces/ or exp

2010 BestBETS

139. The use of senna with docusate for postoperative constipation after pelvic reconstructive surgery: a randomized, double-blind, placebo-controlled trial (Abstract)

The use of senna with docusate for postoperative constipation after pelvic reconstructive surgery: a randomized, double-blind, placebo-controlled trial The objective of the study was to compare time to first bowel movement (BM) after surgery in subjects randomized to placebo or senna with docusate.Ninety-six subjects completed a baseline 7-day bowel diary before and after surgery. After pelvic reconstructive surgery, the subjects were randomized to either placebo (n=45) or senna (8.6 mg

2010 EvidenceUpdates Controlled trial quality: predicted high

140. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of sodium picosulfate in patients with chronic constipation (Abstract)

Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of sodium picosulfate in patients with chronic constipation Although it has been used as a laxative for many years, high-quality trials assessing the efficacy of the laxative sodium picosulfate (SPS) are lacking. The purpose of this study was to assess the efficacy and safety of 4-week treatment with SPS in patients with functional constipation as defined by the Rome III diagnostic criteria.This study was a randomized (...) , double-blind, placebo-controlled, parallel-group study in 45 general practices in Germany. A total of 468 patients with chronic constipation presenting to their general practitioner and fulfilling the Rome III diagnostic criteria were screened. After a 2-week baseline period, 367 patients were randomized to either SPS drops or matching placebo in a 2:1 ratio for 4 weeks. Dose titration was permitted throughout treatment. Patients without a bowel movement for more than 72 h were allowed to use

2010 EvidenceUpdates Controlled trial quality: predicted high